Amneal Pharmaceuticals Inc (OQ:AMRX)
Business Focus: Pharmaceuticals
Apr 16, 2024 08:00 am ET
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the launch of PEMRYDI RTU®, the first and only ready-to-use presentation of pemetrexed for injection. This product does not require reconstitution, dilution, or refrigeration, which is different than other versions of pemetrexed for injection.
Apr 10, 2024 08:00 am ET
Amneal to Report First Quarter 2024 Results on May 3, 2024
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time.
Mar 28, 2024 04:05 pm ET
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the Nasdaq closing bell on Tuesday, April 2, 2024.
Mar 25, 2024 04:05 pm ET
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”) for ciprofloxacin and dexamethasone otic suspension. This product is a combination of ciprofloxacin, a fluoroquinolone antibacterial and dexamethasone, a corticosteroid, and is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients due to staphyl
Mar 01, 2024 06:00 am ET
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December 31, 2023.
Feb 27, 2024 08:00 am ET
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United Kingdom, and Switzerland.
Feb 13, 2024 08:00 am ET
Amneal to Participate at Upcoming Investor Conference
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer, will participate in the following investor conference.
Feb 08, 2024 04:05 pm ET
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has provided a Complete Response resubmission to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa...
Jan 31, 2024 04:05 pm ET
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its fourth quarter and full year 2023 financial results on Friday, March 1, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time.
Jan 25, 2024 07:30 am ET
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal"), granting...
Jan 10, 2024 08:00 am ET
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced the approval and launch of fluorometholone ophthalmic suspension. The product received 180-day competitive generic therapy (CGT) exclusivity from the U.S. Food and Drug Administration, a status that applies to first-marketed generics of key medicines.
Jan 08, 2024 07:00 am ET
INVESTIGATION ALERT: Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and Encourages Long-Term Investors to Contact the Firm
PHILADELPHIA, Jan. 8, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal") on behalf of the Company's shareholders.
Jan 04, 2024 04:05 pm ET
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) today announces that it has launched 39 new retail and injectable medicines in 2023, as compared to 26 new launches in 2022.
Dec 27, 2023 08:30 am ET
AMNEAL INVESTIGATION NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and Encourages Investors with Losses to Contact the Firm
Kaskela Law LLC announces that it is investigating Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) on behalf of the Company’s shareholders. Since March 2019, shares of Amneal’s common stock have declined in value from over $14.00 per share...
Dec 21, 2023 08:00 am ET
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. Chirag will present on January 10th at 11:15 AM PST, and a live webcast will be accessible on the Company's website at
Dec 15, 2023 04:05 pm ET
Amneal Announces Move to Nasdaq
Amneal Pharmaceuticals, Inc. (“Amneal”) (NYSE: AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market (“Nasdaq”) from the New York Stock Exchange (“NYSE”). The Company expects the Nasdaq listing to occur on December 27, 2023 and will continue to trade under the current symbol “AMRX”. Upon transferring, Amneal will become part of the Nasdaq Composite Index and Nasdaq Biotechnology Index.
Dec 07, 2023 08:00 am ET
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023. Amneal expects to begin distribution of ONGENTYS® in early 2024.
Dec 01, 2023 08:00 am ET
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) and Strides Pharma Science Limited (“Strides”) today announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®. The product has been in-licensed from Strides, a global pharmaceutical manufacturer, and will be commercialized by Amneal starting in the fourth quarter of 2023.
Nov 07, 2023 06:00 am ET
Amneal Reports Third Quarter 2023 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the third quarter ended September 30, 2023.
Nov 03, 2023 08:00 am ET
Amneal to Participate at Upcoming Investor Conferences
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the below investor conferences.
Oct 23, 2023 04:05 pm ET
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the third quarter ended September 30, 2023. The Company also raised its financial guidance for the year ending December 31, 2023, which was most recently issued on August 4, 2023. The Company plans to report actual third quarter 2023 financial results on November 7, 2023.
Oct 12, 2023 08:00 am ET
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the addition of two denosumab biosimilars referencing both Prolia® and XGEVA® to its biosimilar pipeline.
Oct 05, 2023 08:00 am ET
Amneal to Report Third Quarter 2023 Results on November 7, 2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time.
Sep 06, 2023 04:00 pm ET
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”) for calcium gluconate in sodium chloride injection, 1000 mg/50 mL and 2000 mg/100 mL. This injectable product is currently on the U.S. FDA shortage product list.
Sep 06, 2023 08:01 am ET
Amneal Receives First Product Approval in China
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received its first product approval in China. Sevelamer carbonate was approved and is expected to launch shortly. In addition, the Company expects to launch oseltamivir phosphate in China this year as well, upon approval. In total, Amneal has 6 products pending review in China with more product registrations planned over time. Since 2019, the Company has collaborated with Fosun Pharmaceuticals to bring key therapies to market in China.
Sep 06, 2023 08:00 am ET
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for lisdexamfetamine dimesylate capsules, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.
Aug 29, 2023 04:01 pm ET
Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that a delegation of senior members of the U.S. Department of Health and Human Services (HHS) and U.S. Food and Drug Administration (FDA) together with local government officials recently visited the Company’s manufacturing facility in Matoda, India. The visit followed the G20 Health Ministers' meeting in Gandhinagar, India on August 18 and 19, where health ministers from around the world met to discuss global health issues.
Aug 25, 2023 08:00 am ET
Amneal to Participate at the 2023 Wells Fargo Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Wells Fargo Healthcare Conference on September 7, 2023 in Boston. Mr. Patel will also be hosting a fireside chat at 8:00 AM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's website at
Aug 24, 2023 04:01 pm ET
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that JAMA Neurology has published results from the RISE-PD clinical study assessing the efficacy and safety of IPX203 versus optimized immediate-release carbidopa/levodopa (IR CD/LD) for the treatment of Parkinson’s disease (PD). The study met its primary and secondary endpoints finding that IPX203 provided more hours of “Good On” time per day, less “Off” time per day, and more “Good On” time per dose than optimized IR CD/LD, even when dosed less frequently. “Good On” time is defined as the sum of “On” time without dyskinesia and
Aug 04, 2023 06:00 am ET
Amneal Reports Second Quarter 2023 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the second quarter ended June 30, 2023.
Jul 26, 2023 08:00 am ET
Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has submitted Abbreviated New Drug Applications (“ANDA”) to the U.S. Food and Drug Administration (FDA) for three key complex generic products, including:
Jul 19, 2023 02:01 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amneal Pharmaceuticals, Inc. - AMRX
Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NYSE: AMRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jul 17, 2023 05:35 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amneal Pharmaceuticals, Inc. - AMRX
NEW YORK, July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE: AMRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 09, 2023 10:34 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amneal Pharmaceuticals, Inc. - AMRX
Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NYSE: AMRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jul 06, 2023 08:00 am ET
Amneal to Report Second Quarter 2023 Results on August 4, 2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2023 financial results on Friday August 4, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on August 4, 2023.
Jul 05, 2023 09:31 am ET
Thinking about buying stock in Oncolytics Biotech, Eos Energy Enterprises, Rivian Automotive, Carnival Corp, or Amneal Pharmaceuticals?
NEW YORK, July 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCY, EOSE, RIVN, CCL, and AMRX.
Jul 03, 2023 02:01 pm ET
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the launch of its authorized generic for Xyrem®1 (Sodium Oxybate) oral solution CIII in the United States. Sodium Oxybate oral solution, 0.5 g/mL is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy. In addition, the Company announced it has received Abbreviated New Drug Application (ANDA) approvals from the U.S. Food and Drug Administration (“FDA”) for five co
Jul 03, 2023 02:00 pm ET
Amneal Receives U.S. FDA Complete Response Letter for IPX203
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s New Drug Application (NDA) for IPX203 for the treatment of Parkinson’s disease.
Jun 15, 2023 08:00 am ET
Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its third annual (2022) Environmental, Social and Governance (ESG) Report. This 2022 report provides a look at our progress across our ESG focus areas, including updates to our people data and sustainability programs.
Jun 14, 2023 08:00 am ET
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the 505(b)(2) New Drug Application (NDA) approval from the U.S. Food and Drug Administration (“FDA”) for PEMRYDI RTU®. This product is the first and only ready-to-use presentation of pemetrexed for injection and does not require reconstitution, dilution, or refrigeration. This injectable will be available in three vial sizes: 100mg/10mL; 500 mg/50mL; and 1,000mg/100mL. The Company expects to launch this product in the first quarter of 2024 with a J-Code from the Centers for Medicare & Medicaid Serv
May 24, 2023 08:00 am ET
Amneal to Participate at the 2023 Jefferies Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Jefferies Healthcare Conference held on June 7, 2023 in New York City. Mr. Patel will also be hosting a presentation at 2:30 PM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's website at
May 16, 2023 08:00 am ET
Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of FYLNETRA™ (pegfilgrastim-pbbk), a biosimilar referencing Neulasta® in a pre-filled single-dose syringe. FYLNETRA™ is used to treat neutropenia (low neutrophils which are a type of white blood cells that fight infection) which is commonly experienced by patients undergoing chemotherapy. This product was developed in collaboration with Kashiv Biosciences, LLC located in Chicago, Illinois. The J-Code (Q5130) from the Centers for Medicare & Medicaid Services (CMS) for FYLNETRA™
May 05, 2023 06:00 am ET
Amneal Reports First Quarter 2023 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its actual results today for the first quarter ended March 31, 2023.
Apr 17, 2023 08:00 am ET
Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 22nd Annual Needham Virtual Healthcare Conference held on April 19, 2023. Mr. Patel will also be hosting a fireside chat at 11:45 AM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's website at
Apr 17, 2023 06:30 am ET
Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced certain unaudited preliminary financial results for the first quarter ended March 31, 2023. The Company is also affirming financial guidance for the year ending December 31, 2023, which was previously issued on March 2, 2023. The Company plans to report actual first quarter 2023 financial results on May 5, 2023.
Apr 12, 2023 08:00 am ET
Amneal to Report First Quarter 2023 Results on May 5, 2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2023 financial results on Friday May 5, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 5, 2023.
Mar 02, 2023 06:01 am ET
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan® and is used in the treatment of a known or suspected opioid overdose emergency.
Mar 02, 2023 06:00 am ET
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the fourth quarter and full year ended December 31, 2022.
Jan 31, 2023 08:00 am ET
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2023.
Jan 04, 2023 09:00 am ET
Amneal Announces Strategic European Partnership with Orion Corporation
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has signed a long-term license agreement with Orion Corporation (OMXH: ORNBV & ORNAV) to commercialize a number of Amneal’s complex generic products.
Dec 20, 2022 08:00 am ET
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Company has successfully launched 26 new generic products in 2022. In the fourth quarter of 2022, the Company launched 8 new generic products, including clindamycin phosphate gel 1%, ipratropium bromide nasal sprays, and prednisolone sodium phosphate oral solution.
Nov 23, 2022 08:00 am ET
Amneal to Participate at Upcoming Investor Conferences
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that the management team will attend the following investor conferences:
Nov 22, 2022 04:05 pm ET
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of RELEUKO® (filgrastim-ayow), a biosimilar referencing Neupogen®. RELEUKO® is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy. This product was developed in collaboration with Kashiv Biosciences, LLC located in Chicago, Illinois.
Nov 11, 2022 08:00 am ET
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for IPX203 for the treatment of Parkinson’s disease (PD). IPX203 is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules.
Nov 04, 2022 06:00 am ET
Amneal Reports Third Quarter 2022 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the third quarter ended September 30, 2022.
Nov 02, 2022 08:00 am ET
Amneal Receives FDA Approval for Leuprolide Acetate Injection
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for leuprolide acetate for injection.
Oct 31, 2022 04:05 pm ET
Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has appointed Reem Malki as Senior Vice President, Chief Quality Officer, and Maryll W. Toufanian as Senior Vice President, Regulatory Strategy and Policy.
Oct 06, 2022 08:00 am ET
Amneal to Report Third Quarter 2022 Results on November 4, 2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2022 financial results on Friday November 4, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on November 4, 2022.
Oct 03, 2022 04:05 pm ET
Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of ALYMSYS® (bevacizumab-maly), a biosimilar referencing Avastin®. ALYMSYS® is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals.
Sep 06, 2022 04:05 pm ET
Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty, effective September 6, 2022.
Aug 31, 2022 04:35 pm ET
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease (PD).
Aug 22, 2022 04:05 pm ET
Amneal supports Congress’ efforts to ensure essential medicines are Made in America
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced its support of the creation of the bipartisan Congressional Domestic Pharmaceutical Manufacturing Caucus. This caucus will focus on securing America’s pharmaceutical supply chain by ensuring that essential medicines are manufactured in the U.S. This working group will led by Rep. Gus Bilirakis (R-FL), Rep. Earl L. "Buddy" Carter (R-GA), Rep. Chrissy Houlahan (D-PA), and Rep. Elissa Slotkin (D-MI).
Aug 11, 2022 04:05 pm ET
Amneal launches 4 new Generic products, including Vasopressin single-dose
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for four generics products, including vasopressin injection 1mL (single-dose).
Aug 05, 2022 06:00 am ET
Amneal Reports Second Quarter 2022 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the second quarter ended June 30, 2022.
Aug 03, 2022 08:00 am ET
Amneal Appoints Deborah M. Autor to Board of Directors
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that Deborah M. Autor has been appointed to the Company’s Board of Directors, effective July 29, 2022.
Jul 08, 2022 08:00 am ET
Amneal to Report Second Quarter 2022 Results on August 5, 2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2022 financial results on Friday August 5, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on August 5, 2022.
Jun 07, 2022 08:00 am ET
Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its second annual (2021) Corporate Responsibility Report. The report showcases the Company’s continued progress in deepening its commitment to environmental, social, and governance (ESG) integration across Amneal strategy, culture and operations. Updates on actions the Company has taken in key ESG areas are highlighted alongside the social impacts of our business as well as the latest information on our diversity data, employee development and well-being offerings, environmental programs and re
Jun 01, 2022 08:00 am ET
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of LYVISPAH®, a baclofen oral granules (5, 10 and 20 mg) specialty product approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of spasticity related to multiple sclerosis and other spinal cord disorders.
May 27, 2022 06:00 am ET
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta®. The product will be marketed under the proprietary name FYLNETRA™.
May 24, 2022 08:00 am ET
Amneal to Participate at the 2022 Jefferies Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2022 Jefferies Healthcare Conference held on June 8, 2022 in New York City. Mr. Patel will also be hosting a presentation which will begin at 8:00 AM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's website at
May 13, 2022 08:00 am ET
Amneal to Participate at Upcoming Investor Conferences in May
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its investor relations or management team will attend the following investor conferences:
May 04, 2022 06:00 am ET
Amneal Reports First Quarter 2022 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the first quarter ended March 31, 2022.
Apr 13, 2022 04:01 pm ET
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin®. The product will be marketed under the proprietary name ALYMSYS® and represents the third bevacizumab biosimilar approved in the U.S.
Apr 07, 2022 08:00 am ET
Amneal to Report First Quarter 2022 Results on May 4, 2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2022 financial results on Wednesday, May 4, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 4, 2022.
Mar 24, 2022 08:00 am ET
Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that results from the pivotal Phase 3 RISE-PD clinical trial evaluating the novel investigational extended-release CD/LD formulation, IPX-203, in Parkinson’s disease patients with motor fluctuations, will be presented at the 2022 American Academy of Neurology (AAN) Annual Meeting, April 2-7, in Seattle, WA.
Mar 17, 2022 04:05 pm ET
Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income Countries
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has been awarded a sub-license from the Medicines Patent Pool (MPP) to manufacture and commercialize a generic version of nirmatrelvir, co-packaged with ritonavir, in 95 low- and middle-income countries. Nirmatrelvir is an oral protease inhibitor co-packaged with ritonavir for the treatment of mild-to-moderate COVID-19.
Mar 02, 2022 06:00 am ET
Amneal Reports Fourth Quarter and Full Year 2021 Financial Results
“2021 was a transformational year for Amneal as we delivered strong financial results, including 18 percent adjusted EBITDA growth, and advanced our evolution into a diversified biopharmaceutical company. We continued to deepen our robust R&D pipeline and added compelling assets in key growth areas – including Injectables, Specialty and Biosimilars. We enter 2022 feeling great about our future growth prospects and well positioned as we focus on further diversifying and scaling in high-growth markets. We are proud of our team’s execution and confident in creating substantial value for all stake
Mar 01, 2022 04:05 pm ET
Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of the Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen®. The product will be marketed under the proprietary name RELEUKOTM.
Feb 17, 2022 08:00 am ET
Amneal Expands Injectables Portfolio with 4 New Products
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the approval of four generic injectables products. Dexamethasone sodium phosphate injection, USP 10 mg/mL, azacitidine 100 mg, carboprost tromethamine injection, USP 250 mcg/mL, and atropine sulfate injection, USP 0.5 mg/5 mL, have received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA). Dexamethasone and azacitidine are both currently on the FDA drug shortage list, and atroprine was granted Competitive Generic Therapy (CGT) status by the FDA.
Feb 04, 2022 08:00 am ET
Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced today that the Company will release its fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2022.
Jan 05, 2022 06:05 am ET
Amneal Acquires Saol Therapeutics’ Baclofen Franchise
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and Saol Therapeutics, a private specialty pharmaceutical company (“Saol”), today announced a definitive agreement under which Amneal will acquire Saol’s Baclofen franchise, including Lioresal® and LYVISPAHTM as well as a pipeline product under development. The acquisition expands Amneal’s commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market. The transaction is expected to be accretive to Amneal’s adjusted EB
Dec 21, 2021 08:00 am ET
Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal’s Co-Chief Executive Officer and President, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022 at 11:15 AM Eastern Time. A live webcast of the presentation and subsequent Q&A session will be accessible through the Investor Relations section of the Company's website at
Nov 19, 2021 08:00 am ET
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for difluprednate ophthalmic emulsion 0.05%, which is the generic version of Durezol® and is used in the treatment of inflammation and pain associated with ocular surgery.
Nov 12, 2021 08:00 am ET
Amneal to Virtually Participate at Upcoming Investor Conferences
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its investor relations or management team will virtually attend the following investor conferences:
Nov 03, 2021 06:00 am ET
Amneal Reports Third Quarter 2021 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the third quarter ended September 30, 2021.
Nov 02, 2021 08:00 am ET
Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its inaugural Corporate Responsibility Report with primarily 2020 data and select 2021 highlights. This initial report provides stakeholders with details around the Company’s commitment to good environmental, social and governance (ESG) practices that are strategic, impactful, and embedded into the Company’s culture. The report highlights five key areas of impact relating to the Company’s people, products, governance, planet and community, and includes a deeper look at Amneal’s role in t
Oct 27, 2021 08:00 am ET
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA).
Oct 06, 2021 08:00 am ET
Amneal to Report Third Quarter 2021 Results on November 3, 2021
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2021 financial results on Wednesday, November 3, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on November 3, 2021.
Sep 07, 2021 08:00 am ET
Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that members of management will participate at the Morgan Stanley Global Healthcare Conference held on September 15, 2021. The presentation will begin at 1:15 PM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's website at
Aug 26, 2021 08:30 am ET
Thinking about buying stock in Pure Storage, Zuora, Amneal Pharmaceuticals, Lordstown Motors, or VEON?
NEW YORK, Aug. 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTG, ZUO, AMRX, RIDE, and VEON.
Aug 25, 2021 04:01 pm ET
Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced positive topline results from the pivotal Phase 3 RISE-PD clinical trial that evaluated the novel formulation, IPX-203, in patients with Parkinson’s disease (PD) who have motor fluctuations. The trial met its primary endpoint, demonstrating superior “Good On” time from baseline in hours per day at the end of the 13-week double-blind treatment period with IPX-203 CD/LD extended-release capsules compared with immediate-release CD/LD. Based on these topline results plus other supportive data, Amneal plans to submit a New Drug Application (
Aug 23, 2021 08:00 am ET
Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will host a virtual event for the investment community on Wednesday, August 25, 2021 at 4:30 p.m. ET. The upcoming event will feature members of Amneal’s management team as well as Alberto Espay, MD, MSc, FAAN, FANA (University of Cincinnati), and Robert A Hauser, MD, MBA, FAAN (University of South Florida). The presentation will be followed by a live Q&A session.
Aug 09, 2021 06:00 am ET
Amneal Reports Second Quarter 2021 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) (the “Company”) announced its results today for the second quarter ended June 30, 2021.
Jul 20, 2021 08:30 am ET
Thinking about buying stock in Neurobo Pharmaceuticals, Xenetic Biosciences, Amneal Pharmaceuticals, PLx Pharma, or Orbital Energy Group?
NEW YORK, July 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NRBO, XBIO, AMRX, PLXP, and OEG.
Jul 19, 2021 04:32 pm ET
Amneal Receives Approval for Generic TobraDex®
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio.
Jul 15, 2021 08:00 am ET
Amneal to Report Second Quarter 2021 Results on August 9, 2021
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2021 financial results on Monday, August 9, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:00 a.m. Eastern Time on August 9, 2021.
Jun 17, 2021 08:00 am ET
Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Bevacizumab, pursuant to Section 351(k) pathway of the Public Health Service Act, and with a standard review goal date in the second quarter of 2022 according to the BsUFA (Biosimilar User Fee Act).
Jun 07, 2021 08:00 am ET
Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Food and Drug Administration recently accepted Amneal’s 505(b)(2) New Drug Application for a newly licensed dihydroergotamine (DHE) prefilled syringe autoinjector and the company said it anticipates a decision by the middle of 2022. If approved, Amneal anticipates a commercial launch in the second half of 2022. Amneal plans to commercialize the product solely in the U.S. market.
May 14, 2021 09:00 am ET
Amneal to Virtually Participate at Upcoming Investor Conferences
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences:
May 07, 2021 06:00 am ET
Amneal Reports First Quarter 2021 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the first quarter ended March 31, 2021.
Apr 15, 2021 08:00 am ET
Amneal to Report First Quarter 2021 Results on May 7, 2021
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2021 financial results on Friday, May 7, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 7, 2021.
Apr 05, 2021 08:00 am ET
Amneal Completes Acquisition of Kashiv Specialty Pharmaceuticals
Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE: AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced that Amneal Pharmaceuticals LLC (“Amneal”), a subsidiary of the Company, has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“Kashiv Specialty”), a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.
Feb 26, 2021 06:02 am ET
Amneal Receives Approval for Generic Version of Ortho Evra®
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for 150 mcg/day Norelgestromin and 35 mcg/day Ethinyl Estradiol Transdermal System. In conjunction with its approval, Amneal received a Competitive Generic Therapy (CGT) designation by the FDA and has been granted 180 days of exclusivity.
Feb 26, 2021 06:00 am ET
Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and full year ended December 31, 2020.
Feb 22, 2021 04:05 pm ET
Amneal to Virtually Participate at Upcoming Investor Conferences
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences:
Feb 04, 2021 08:00 am ET
Amneal to Report Fourth Quarter & Full Year 2020 Results on February 26, 2021
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2020 financial results on Friday, February 26, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on February 26, 2021.
Jan 12, 2021 06:00 am ET
Amneal to Acquire Substantially All of Kashiv Specialty Pharmaceuticals
Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE:AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced they have entered into a definitive agreement under which Amneal Pharmaceuticals LLC (“Amneal”), a wholly-owned subsidiary of the Company, will acquire a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“Kashiv Specialty”), a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drug
Jan 08, 2021 08:00 am ET
Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that it has received approval of an additional strength of 500 mg to its Abbreviated New Drug Application (ANDA), from the U.S. Food and Drug Administration (FDA) for Abiraterone Acetate Tablets, USP, 250 mg and 500 mg. This ANDA is approved for its use in combination with Prednisone. Abiraterone Acetate Tablets, USP, 250 mg and 500 mg, are the generic version of Zytiga® for treatment of metastatic prostate cancer. Amneal immediately initiated commercialization activities upon the approval of the additio
Jan 05, 2021 09:23 am ET
Amneal to Virtually Participate at the 39th Annual J.P. Morgan Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal’s Co-Chief Executive Officer and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021 at 2:50 PM Eastern Time. A live webcast of the presentation will be accessible through the Investor Relations section of the Company's website at
Nov 11, 2020 08:35 am ET
Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%. Acyclovir Cream, 5%, is the generic version of Zovirax® for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The product is available by prescription only and is associated with mild side effects such as nausea.
Nov 06, 2020 06:00 am ET
Amneal Reports Third Quarter 2020 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the third quarter ended September 30, 2020.
Oct 15, 2020 08:00 am ET
Amneal to Report Third Quarter 2020 Results on November 6, 2020
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2020 financial results on Friday, November 6, 2020, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on November 6, 2020.
Oct 08, 2020 03:10 pm ET
Company Profile for Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc. (NYSE:AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Oct 08, 2020 08:00 am ET
Amneal & PL Developments Launch Store Brand Program of Over-the-Counter (“OTC”) Diclofenac Sodium Topical Gel, 1%
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal’ or the “Company”) and PL Developments (PLD) today announced that they have commenced shipments of store brand equivalent Voltaren® Arthritis Pain Gel (diclofenac sodium topical gel, 1%) in 50, 100 and 150g laminate tubes following FDA clearance. Amneal and PLD have partnered to bring this important product to US retailers.
Sep 01, 2020 08:00 am ET
Amneal to Virtually Participate at the Morgan Stanley Global Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that members of management will participate at the Morgan Stanley Global Healthcare Conference held on September 15, 2020. The presentation will begin at 4:15 PM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's website at
Aug 25, 2020 09:00 am ET
Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5%
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Lidocaine Patch, 5%. Lidocaine Patch, 5% is the generic version of Lidoderm Patch, 5% for treatment of post-herpetic neuralgia.
Aug 12, 2020 08:01 am ET
Wishbone Medical Appoints Jeff George to Board of Directors
WishBone Medical, Inc., a leader in pediatric orthopedic medical devices, is pleased to announce the appointment of Jeff George, global healthcare executive and investor, to the company’s board of directors, effective August 12, 2020. “As WishBone...
Aug 06, 2020 06:00 am ET
Amneal Reports Second Quarter 2020 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the second quarter ended June 30, 2020.
Jul 14, 2020 07:00 am ET
Cosette Pharmaceuticals Appoints Seasoned Industry Executive Apurva Saraf as President and Chief Executive Officer
Cosette Pharmaceuticals, Inc. (“Cosette” or the “Company”), a privately held specialty generic pharmaceutical company primarily focused on extended topical and suppository products, announced today the appointment of Apurva Saraf as President and...
Jul 13, 2020 08:30 am ET
Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has appointed Todd Branning as Chief...
Jul 10, 2020 09:31 am ET
Thinking about buying stock in Unum Therapeutics, Nokia, Amneal Pharmaceuticals, Aytu Bioscience, or Niu Technologies?
NEW YORK, July 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UMRX, NOK, AMRX, AYTU, and NIU.
Jul 10, 2020 08:00 am ET
Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg. Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia. Amneal immediately initiated commercialization activities across all dosages.
Jul 08, 2020 08:00 am ET
Amneal to Report Second Quarter 2020 Results on August 6, 2020
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2020 financial results on Thursday, August 6, 2020, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on August 6, 2020.
May 11, 2020 06:30 am ET
Amneal Reports First Quarter 2020 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the first quarter ended March 31, 2020.
Apr 24, 2020 04:05 pm ET
Amneal to Report First Quarter 2020 Results on May 11, 2020
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2020 financial results on Monday, May 11, 2020, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 11, 2020.
Apr 16, 2020 07:00 am ET
Amneal Launches Generic Butrans® Following ANDA Approval by FDA
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Butrans® (buprenorphine) Transdermal System, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr. In addition, Amneal was granted the Competitive Generic Therapy (CGT) designation and 180 days of exclusivity for the 7.5 mcg/hr dose. Amneal immediately initiated commercialization activities across all dosages for its Buprenorphine Transdermal Sys
Apr 15, 2020 04:30 pm ET
Amneal Pharmaceuticals Moving to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will be a virtual meeting instead of an in-person meeting. This change is in response to the ongoing COVID-19 pandemic and is intended to protect the health and safety of Amneal’s stockholders and employees.
Mar 26, 2020 04:30 pm ET
State of Texas and Senator Bryan Hughes Secure a Donation of Hydroxychloroquine Sulfate from Amneal Pharmaceuticals for Texas Patients
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”), one of the largest U.S.-based generics manufacturers, and the State of Texas today announced that they are responding to the national COVID-19 health emergency. Amneal has donated 1,000,000 hydroxychloroquine sulfate tablets to the Texas State Pharmacy, which will be directly distributed to hospitals for potential use in treating COVID-19 patients.
Mar 23, 2020 09:31 am ET
Thinking about buying stock in Amneal Pharmaceuticals, B2Gold, Chesapeake Energy Corp, Hepion Pharmaceuticals, or Waitr?
NEW YORK, March 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMRX, BTG, CHK, HEPA, and WTRH.
Mar 20, 2020 04:15 pm ET
Amneal Accelerates Distribution and Production of Hydroxychloroquine Sulfate to Meet Potential Needs of COVID-19 Patients Nationwide
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”), one of the largest U.S.-based generics manufacturers, today announced that it is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate.
Mar 11, 2020 05:36 pm ET
Amneal Pharmaceuticals Appoints Tasos Konidaris as Senior Vice President, Chief Financial Officer
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has appointed Tasos Konidaris as Senior Vice President, Chief Financial Officer, effective March 12, 2020. Mr. Konidaris succeeds Todd Branning, who is no longer serving in this role, but remains available to the Company through March 31, 2020.
Feb 26, 2020 06:30 am ET
Amneal Reports Fourth Quarter and Full Year 2019 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the fourth quarter and full year ended December 31, 2019.
Jan 24, 2020 06:59 am ET
Amneal to Report Fourth Quarter and Full Year 2019 Results on February 26, 2020
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) announced today that the Company will release its fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on February 26, 2020.
Dec 26, 2019 04:15 pm ET
Amneal Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will present at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 15, 2020.
Dec 16, 2019 06:59 am ET
Amneal Appoints Jeff George, John Kiely and Shlomo Yanai to Board of Directors
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that Jeff George, John Kiely and Shlomo Yanai have been appointed to the Company’s Board of Directors, effective as of December 14, 2019. These three new independent directors bring to Amneal extensive records of overseeing growth and creating value in the pharmaceutical and healthcare industries.
Dec 12, 2019 06:59 am ET
Amneal Receives Abbreviated New Drug Application Approval for EluRyng™, the First Generic NuvaRing®
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for EluRyng™ (etonogestrel/ethinyl estradiol vaginal ring), the first generic version of NuvaRing®. Amneal has initiated commercialization activities for EluRyng, which is being manufactured internally and launching today.
Dec 10, 2019 06:59 am ET
Amneal to Acquire Majority Interest in AvKARE, Enhancing Access to Growing Federal Healthcare Market
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and AvKARE Inc. today announced they have entered into a definitive agreement under which Amneal will acquire a 65.1% majority interest in AvKARE and its related affiliate doing business as R&S Northeast (collectively, “AvKARE”) for an implied enterprise value of $340 million. Following the close of the transaction, AvKARE will operate on a standalone basis as an independent subsidiary of Amneal.
Dec 03, 2019 08:00 am ET
Amneal Announces the Approval and Launch of Generic Carafate®
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received final U.S. Food and Drug Administration approval on its Abbreviated New Drug Application for a generic version of Carafate® (sucralfate) Oral Suspension, 1 g/10 ml. Amneal has immediately initiated commercialization activities.
Dec 02, 2019 04:05 pm ET
Amneal Announces the Approval and Launch of Generic Revatio® for Oral Suspension and Generic Amicar® Tablets
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received final U.S. Food and Drug Administration (“FDA”) approval on its Abbreviated New Drug Applications (“ANDA”) for generic versions of Revatio® (sildenafil citrate) for Oral Suspension 10 mg/ml and Amicar® (aminocaproic acid) Tablets USP, 500 mg. Amneal has immediately initiated commercialization activities.
Nov 26, 2019 08:05 am ET
Amneal Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that management will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference in New York on Tuesday, December 3, 2019 at 10:00 a.m. Eastern Time.
Nov 06, 2019 06:32 am ET
Amneal Reports Third Quarter 2019 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the third quarter ended September 30, 2019.
Nov 06, 2019 06:30 am ET
Amneal Enters into a Licensing Agreement with Kashiv BioSciences, LLC to Develop and Commercialize K127 for the Treatment of Myasthenia Gravis
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has entered into a licensing agreement with Kashiv BioSciences, LLC for the development and commercialization of Kashiv’s orphan drug K127 (pyridostigmine) for the treatment of Myasthenia Gravis. Through this partnership, Amneal gains exclusive rights within the United States (U.S.) to the New Drug Application (NDA) and commercialization of K127.
Oct 10, 2019 09:25 am ET
Amneal Announces Launch of Generic Invega®
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has launched its generic version of Invega® (paliperidone) extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg.
Oct 09, 2019 08:30 am ET
Amneal to Report Third Quarter 2019 Results on November 6, 2019
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its third quarter 2019 financial results on Wednesday, November 6, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on November 6, 2019.
Sep 05, 2019 09:25 am ET
Amneal Announces Approval of Generic Version of Amicar®
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its generic version of Amicar® (aminocaproic acid oral solution) 0.25g/mL.
Sep 03, 2019 08:35 am ET
Amneal Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate in a fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference in New York on Tuesday, September 10, 2019 at 2:55 p.m. Eastern Time.
Aug 08, 2019 11:13 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amneal Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or “the Company”) (NYSE: AMRX) for violations of §§10(b) and 20(a) of the...
Aug 05, 2019 06:01 am ET
Amneal Reports Second Quarter 2019 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the second quarter ended June 30, 2019.
Aug 05, 2019 06:00 am ET
Amneal Pharmaceuticals Co-Founders Chirag Patel and Chintu Patel Return as Co-Chief Executive Officers
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that its Co-Founders, Chirag Patel and Chintu Patel, have been named Co-Chief Executive Officers, effective immediately. Paul Meister has been appointed to the Board of Directors as Chairman. Additionally, Paul Bisaro and Rob Stewart have resigned as Executive Chairman, and President and Chief Executive Officer, respectively, and have stepped down from the Board. Mr. Stewart will serve as an advisor to the Company through a transition period.
Jul 30, 2019 10:30 am ET
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Amneal Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or “the Company”) (NYSE: AMRX) for violations of §§10(b) and 20(a) of the...
Jul 26, 2019 05:25 pm ET
Jul 24, 2019 04:42 pm ET
AMRX INVESTIGATION ALERT: Bernstein Liebhard LLP Announces Investigation of Amneal Pharmaceuticals Inc.— AMRX
Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Amneal Pharmaceuticals Inc. (“Amneal” or the “Company”) (NYSE: AMRX) resulting from allegations...
Jul 23, 2019 11:43 am ET
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amneal Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or “the Company”) (NYSE: AMRX) for violations of §§10(b) and 20(a) of the...
Jul 22, 2019 07:00 am ET
Amneal Announces Launch of Generic Lyrica®
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received approval for, and launched, its generic version of Lyrica® (pregabalin capsules) 25 mg, 50 mg, 75, mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg.
Jul 18, 2019 03:57 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amneal Pharmaceuticals, Inc. - AMRX
Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NYSE: AMRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Jul 16, 2019 11:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amneal Pharmaceuticals, Inc. - AMRX
NEW YORK, July 16, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE: AMRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Jul 16, 2019 11:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amneal Pharmaceuticals, Inc. - AMRX
NEW YORK, July 16, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE: AMRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Jul 15, 2019 12:02 pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amneal Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or “the Company”) (NYSE: AMRX) for violations of §§10(b) and 20(a) of the...
Jul 12, 2019 10:50 pm ET
AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX).
Jul 11, 2019 12:17 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amneal Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or “the Company”) (NYSE:
Jul 11, 2019 10:10 am ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Amneal Pharmaceuticals, Inc. – AMRX
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) resulting from allegations that Amneal may have issued materially misleading business information to the investing public.
Jul 10, 2019 11:17 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Amneal Pharmaceuticals, Inc. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or “the Company”) (NYSE:
Jul 10, 2019 04:48 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amneal Pharmaceuticals, Inc. - AMRX
Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NYSE: AMRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Jul 10, 2019 06:45 am ET
Amneal Pharmaceuticals Announces Restructuring and Costs Savings Plan to Improve Operations and Position the Company for Future Growth
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced a comprehensive restructuring plan designed to reduce its cost base, further right size its organization and optimize its global manufacturing infrastructure.
Jul 09, 2019 08:45 am ET
Amneal to Report Second Quarter 2019 Results on August 8, 2019
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its second quarter 2019 financial results on Thursday, August 8, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on August 8, 2019.
Jun 26, 2019 09:30 pm ET
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Rockwell Medical, Amneal Pharmaceuticals and Intuit and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Rockwell Medical, Inc., Amneal Pharmaceuticals, Inc., and Intuit, Inc. Additional information about each case can be found at the link provided....
Jun 18, 2019 11:09 am ET
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Rockwell Medical, Amneal Pharmaceuticals, Kraft Heinz, and Intuit and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Rockwell Medical, Amneal Pharmaceuticals, Kraft Heinz, and Intuit. Additional information about each case can be found at the link provided....
Jun 06, 2019 08:35 am ET
Amneal Pharmaceuticals to Present at Upcoming Investor Conferences
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members
of management will participate at the following upcoming investor
conferences:
May 17, 2019 10:50 pm ET
AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a
partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces
that KSF has commenced an investigation into Amneal Pharmaceuticals,
Inc. (NYSE: AMRX).
May 15, 2019 09:25 am ET
Amneal Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that members of
management will participate in a fireside chat at the RBC Capital
Markets Global Healthcare Conference in New York on Tuesday, May 21,
2019 at 11:00 a.m. Eastern Time.
May 13, 2019 05:49 pm ET
AMNEAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Amneal Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, May 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE:AMRX).
May 09, 2019 06:30 am ET
Amneal Reports First Quarter 2019 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”)
announced its results today for the first quarter ended March 31, 2019.
Apr 08, 2019 08:05 am ET
Amneal to Report First Quarter 2019 Results on May 9, 2019
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its first
quarter 2019 financial results on Thursday, May 9, 2019, prior to the
open of the U.S. financial markets. The Company will host a conference
call and live webcast with the investment community at 8:30 a.m.,
Eastern Time on May 9, 2019.
Apr 02, 2019 07:00 am ET
Amneal Names Pradeep Bhadauria as Chief Scientific Officer
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced
that the company has appointed Pradeep Bhadauria as Chief
Scientific Officer (CSO), effective immediately. He will succeed current
CSO Dr. Shankar Hariharan, who is leaving Amneal on May 24, 2019.
Apr 01, 2019 08:31 am ET
Amneal Announces Agreement with Zentiva to Divest Creo Pharma
BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has entered into an agreement with Zentiva Group a.s., under which Zentiva has acquired Creo Pharmaceuticals Ltd., a subsidiary of Amneal that operates the company's commercial operations in the United Kingdom.
Mar 12, 2019 08:30 am ET
Amneal Announces Launch of Rivastigmine Transdermal System
BRIDGEWATER, N.J., March 12, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has launched its generic version of Exelon® Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Company received FDA approval of its Rivastigmine Transdermal System in January 2019, and has received final approval on 10 Abbreviated New Drug Applications this year.
Mar 06, 2019 07:35 am ET
Amneal Pharmaceuticals to Present at the Barclays Global Healthcare Conference
BRIDGEWATER, N.J., March 6, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate in a fireside chat at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami on Wednesday, March 13, 2019.
Feb 28, 2019 06:30 am ET
Amneal Reports Fourth Quarter And Full Year 2018 Financial Results
BRIDGEWATER, N.J., Feb. 28, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and year ended December 31, 2018.
Jan 24, 2019 06:30 am ET
Amneal to Report Fourth Quarter and Full Year 2018 Results on February 28, 2019
BRIDGEWATER, N.J., Jan. 24, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on February 28, 2019.
Jan 22, 2019 05:55 am ET
Amneal Names Accomplished Finance Executive Todd P. Branning As Chief Financial Officer
BRIDGEWATER, N.J., Jan. 22, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it has appointed Todd P. Branning as Senior Vice President and Chief Financial Officer, effective today. Mr. Branning will be responsible for leading Amneal's global finance strategies, including oversight for Finance and Accounting, Internal Audit, Investor Relations and Corporate Communications, and Information Technology. Mr. Branning succeeds Bryan Reasons, who will remain with the company through the end of February 2019 to ensure a smooth transition of responsibilities.
Jan 14, 2019 06:30 am ET
Amneal Announces Approval of Rivastigmine Transdermal System
BRIDGEWATER, N.J., Jan. 14, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Exelon® Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Company is planning to commercialize its Rivastigmine Transdermal System shortly.
Jan 04, 2019 06:30 am ET
Amneal Names David A. Buchen Senior Vice President, Chief Legal Officer And Corporate Secretary
BRIDGEWATER, N.J., Jan. 4, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that it has appointed David A. Buchen to the newly expanded role of Senior Vice President, Chief Legal Officer and Corporate Secretary, reporting to President and Chief Executive Officer Robert Stewart. Mr. Buchen will be responsible for leading Amneal's global legal, Intellectual Property (IP) and corporate compliance functions, as well as aligning the company's corporate legal strategies to drive Amneal's continued growth.
Dec 19, 2018 07:35 am ET
Amneal Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
BRIDGEWATER, N.J., Dec. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will present at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Tuesday, January 8, 2019.
Nov 21, 2018 07:35 am ET
Amneal to Present at the 30th Annual Piper Jaffray Healthcare Conference
BRIDGEWATER, N.J., Nov. 21, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will present at the Piper Jaffray Healthcare Conference in New York, NY, on Tuesday, November 27, 2018 at 1:00 p.m. ET.
Nov 12, 2018 05:55 am ET
Amneal Completes Transition Agreement With Lannett Company To Begin Commercialization Of Levothyroxine On December 1st
BRIDGEWATER, N.J., Nov. 12, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it has completed a transition agreement with Lannett Company. Under the terms of the agreement, Amneal will take over the distribution and marketing of Levothyroxine sodium tablets from Lannett beginning December 1, 2018 through March 23, 2019, ahead of when the Company's previously announced 10-year Levothyroxine distribution agreement with Jerome Stevens begins on March 23, 2019.
Nov 07, 2018 05:55 am ET
Amneal Announces Solid Third Quarter 2018 Financial Results
BRIDGEWATER, N.J., Nov. 7, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the quarter ended September 30, 2018.
Oct 25, 2018 10:00 am ET
Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months
BRIDGEWATER, N.J., Oct. 25, 2018 /PRNewswire/ -- Impax Laboratories LLC (the "Company"), a subsidiary of Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that in collaboration with the U.S. Food and Drug Administration (FDA), the Company is extending the expiration dates for certain lots of its epinephrine injection, USP auto-injector, 0.15 mg and 0.3 mg, the authorized generic of Adrenaclick®.
Oct 24, 2018 07:30 am ET
Amneal Announces Issuance of New Patent for IPX203, an Investigational Extended-Release Formulation of Carbidopa-Levodopa
BRIDGEWATER, N.J., Oct. 24, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that a patent protecting IPX203 has been issued by the United States Patent and Trademark Office. U.S. Patent No. 10,098,845 covers controlled release formulations of levodopa and uses thereof.
Oct 23, 2018 07:30 am ET
Amneal Announces Approval and Launch of Clobazam Tablets and Clobazam Oral Suspension
BRIDGEWATER, N.J., Oct. 23, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Onfi® (clobazam) tablets, 10 mg and 20 mg for oral use, CIV, and Onfi ® (clobazam) oral suspension, 2.5 mg/mL ,CIV.
Oct 19, 2018 08:00 am ET
Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch
BRIDGEWATER, N.J., Oct. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of BiCNU® (carmustine) for injection, 100 mg. The Company is planning to commercialize its Carmustine for Injection in November 2018.
Oct 19, 2018 07:30 am ET
Amneal Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP
BRIDGEWATER, N.J., Oct. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of IsuprelTM Injection (isoproterenol hydrochloride) USP, 0.2 mg/mL and 1 mg/5 mL(0.2 mg/mL) Single-Dose Vials. The Company has immediately initiated commercialization activities.
Sep 24, 2018 07:35 am ET
Amneal to Present at the Cantor Fitzgerald Global Healthcare Conference
BRIDGEWATER, N.J., Sept. 24, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference in New York, NY, on Monday, October 1, 2018 at 2:55 p.m. ET.
Sep 21, 2018 08:30 am ET
Amneal to Report Third Quarter 2018 Results on November 7, 2018
BRIDGEWATER, N.J., Sept. 21, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2018 financial results on Wednesday, November 7, 2018, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on November 7, 2018.
Sep 12, 2018 07:30 am ET
Amneal Announces FDA Approval and Launch of Generic Chlorpromazine Hydrochloride Tablets USP and Approval of Methylergonovine Maleate Tablets USP
BRIDGEWATER, N.J., Sept. 12, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application (ANDA) for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg and has immediately initiated commercialization activities. According to IQVIA™, the U.S. market for chlorpromazine hydrochloride tablets USP is estimated to be approximately $207 million in annual sales for the 12 months ended July 2018.
Aug 31, 2018 08:00 am ET
Amneal to Present at Upcoming Investor Conferences
BRIDGEWATER, N.J., Aug. 31, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it plans to participate at the following upcoming investor conferences.
Aug 31, 2018 07:30 am ET
Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches
BRIDGEWATER, N.J., Aug. 31, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena® (hydroxyprogesterone caproate injection, USP, 250mg/mL). The injectable is used to reduce the risk of preterm birth in certain women. According to IQVIA™, the U.S. brand market for Makena is estimated to be approximately $323 million in annual sales for the 12 months ended June 2018.
Aug 20, 2018 07:30 am ET
Amneal Announces 10-Year Licensing and Supply Agreement with Jerome Stevens Pharmaceuticals, Inc. for Levothyroxine
BRIDGEWATER, N.J., Aug. 20, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced a 10-year license and supply agreement for Levothyroxine sodium tablets with Jerome Stevens Pharmaceuticals, Inc. (JSP), a New York-based pharmaceutical manufacturer of prescription tablet and capsule formulations. The agreement is effective March 22, 2019.
Aug 09, 2018 07:00 am ET
Amneal Announces Solid Second Quarter 2018 Financial Results
BRIDGEWATER, N.J., Aug. 9, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the quarter ended June 30, 2018.
Jul 23, 2018 07:30 am ET
Amneal Announces FDA Approval and Launch of Generic Potassium Chloride Oral Solution
BRIDGEWATER, N.J., July 23, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application for a generic version of Potassium Chloride oral solution, 20 mEq per 15mL and 40 mEq per 15 mL, and has immediately initiated commercialization activities.
Jun 29, 2018 08:15 am ET
Amneal to Report Second Quarter 2018 Results on August 9, 2018
BRIDGEWATER, N.J., June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2018 financial results on Thursday, August 9, 2018, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on August 9, 2018.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.